What is TOVX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TOVX?

P/E (TTM) is n/a and 52-week range is $0.16 to $0.86 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TOVX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TOVX?

The company profile lists revenue (TTM) near $298K, net income (TTM) near $-203M, EPS (TTM) near $-0.64 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Theriva Biologics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 45.9M shares outstanding, ISIN US87164U5083 when available from company profile and filing metadata.

Theriva Biologics Inc

$TOVX

Health Care · Biotechnology

IR Run Scenarios

$0.22

-4.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 15 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Employees

Website

therivabio.com/

IPO

1993-02-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)